Efficacy and Safety of Intracoronary versus Intravenous Administration of Tirofiban during Percutaneous Coronary Intervention for Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials.
Percutaneous coronary intervention (PCI) is known as the most effective treatment for acute coronary syndrome (ACS). However, without proper therapy and patient management, stent thrombosis after PCI may lead to another myocardial infarction. In addition to aspirin and clopidogrel, tirofiban is ofte...
Main Authors: | Xiuying Tang, Runjun Li, Quanmin Jing, Yingfeng Liu, Peng Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4465926?pdf=render |
Similar Items
-
Intracoronary versus intravenous administration of tirofiban during percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS) patients
by: S. Pradhan, et al.
Published: (2015-12-01) -
Intracoronary Versus Intravenous Administration of Eptifibatide During Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes
by: tooran makhdoumi
Published: (2020-10-01) -
Intracoronary versus intravenous administration of abciximab in patients with acute coronary syndrome: a meta-analysis.
by: Jie-Ning Wang, et al.
Published: (2013-01-01) -
Antiplatelet medications in acute coronary syndromes and percutaneous coronary interventions: focus on tirofiban
by: T. A. Batyraliev, et al.
Published: (2008-12-01) -
Effects of Intracoronary Pro-urokinase or Tirofiban on Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: A Multi-Center, Placebo-Controlled, Single-Blind, Randomized Clinical Trial
by: Dong Huang, et al.
Published: (2021-08-01)